Immunovant Inc.'s shares fell sharply early Monday after majority shareholder Roivant Sciences Ltd. made a $200 million strategic investment, opting against buying the outstanding minority interest in the clinical-stage biopharmaceutical company.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,